HIV RAPID TESTING AMONG SUBSTANCE ABUSERS

本申请是对NIMH的RO 3奖的请求，以评估药物滥用者中艾滋病毒快速检测的可接受性和可行性。Lally博士是布朗大学全职医学助理教授的第二年。Miriam医院和布朗大学的临床研究培训环境非常适合RO 3。药物滥用者感染艾滋病毒的风险很高，这不仅是因为共用针头和与注射吸毒有关的“工作分担”，而且还因为活性药物滥用者之间的高风险性行为。短期药物滥用治疗（戒毒）是与活跃药物滥用者接触的一个极好的机会，既可用于疾病诊断，也可用于与医疗保健挂钩。大多数戒毒中心不定期提供艾滋病毒检测。相比之下，我们在罗得岛的戒毒中心为住院病人定期提供标准的两次访问艾滋病毒检测，并发现检测很受欢迎。艾滋病毒检测结果的后续行动是全国范围内的一个问题，新技术现在使人们有可能进行快速艾滋病毒检测，以便立即获得结果。Quix（TM）是一种快速的艾滋病毒测试，可以很容易地在戒毒环境管理。将评估在这种情况下快速检测的可行性和可接受性。我们将对所有研究参与者进行ACASI风险评估，然后为他们提供快速检测Quix（TM）和FDA批准的标准Orasure（R）检测的HIV检测。我们将测试220人-55名年轻女性（18-25岁），55名老年女性（>25岁），55名年轻男性（18-25岁）和55名老年男性（>25岁）-他们是药物滥用戒毒中心的住院患者。参与者将在几分钟内获得Quix（TM）测试的测试结果，并鼓励他们获得Orasure（R）测试的结果，这些结果通常将在2-3天内提供。与标准检测相比，快速检测的可接受性和满意度以及随访率将在年轻和老年男性和女性中并根据风险状况进行评估。

This application is a request for an RO3 award from NIMH to evaluate the acceptability and feasibility of rapid testing for HIV among substance abusers. Dr. Lally is in her second year on the full time faculty as an Assistant Professor of Medicine at Brown University. The clinical research training environment at the Miriam Hospital and Brown University is well-suited for an RO3. Substance abusers are at high risk for HIV disease not only because of needle sharing and "sharing of works" associated with injection drug use, but also because of high-risk sexual behavior among active substance abusers. Short-term substance abuse treatment (detoxification) is an excellent opportunity to interface with active substance abusers both for diagnosis of disease and linkage to medical care. Testing for HIV is not routinely offered at most detoxification centers. In contrast, we have routinely offered standard two visit HIV testing to inpatients at detoxification centers in Rhode Island and have found testing to be well received. Follow-up for HIV test results is a problem nation wide, and new technology now makes it possible to do rapid HIV testing so that immediate results are available. Quix(TM) is a rapid HIV test that can be easily administered in the detoxification setting. Feasibility and acceptability of rapid testing in this setting will be evaluated. We will administer an ACASI risk assessment to all study participants and then offer them HIV testing with both the rapid test, Quix(TM), and the standard FDA approved Orasure(R) test. We will test 220 people -55 young women (18-25), 55 older women (>25), 55 young men (18-25), and 55 older men (>25)- who are inpatients at a substance abuse detoxification center. Participants will be provided with their test results from the Quix(TM) test within minutes, and they will also be encouraged to receive the results of their Orasure(R) tests, which generally will be available within 2-3 days. Acceptability and satisfaction of rapid compared to standard testing as well as follow up rates will be evaluated among younger and older men and women and by risk profile.